片頭痛治療薬の世界市場：市場規模・シェア・動向分析 (治療薬別・薬剤クラス別・投与経路別・年齢層別・入手手段別・地域別)、セグメント別予測 (2025年～2030年)

片頭痛治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、片頭痛治療薬の世界市場規模は2030年までに133億4,000万米ドルに達し、2025年から2030年までのCAGRは10.9％を記録すると予測されています。

この市場を大きく牽引しているのは、疾患有病率の上昇、新規治療法の開発、ライフスタイルの変化、ホルモン薬などの要因です。

片頭痛は、3日以上続く激しいズキズキする頭の痛みの再発発作を特徴とする衰弱性神経疾患です。片頭痛の痛みは動くと悪化し、患者が通常の日常生活を送れなくなることもあります。発作の約3分の1では、頭、顔、首の両側が冒されます。

過去5年間、世界の片頭痛治療薬市場は比較的停滞しており、主にジェネリックのトリプタン系薬剤やその他の適応外薬剤が市場を独占しています。現在処方されている薬剤の大半は、急性期治療用、予防治療用ともに有効性が低く、副作用のプロファイルも好ましくないです。

Amgen/NovartisのCGRP mAb AimovigとTeva PharmaのAjovyの発売は、片頭痛予防の治療パラダイムを変革する第一歩です。Eli Lilly社、Alder BioPharma社、Biohaven Pharma社など、2019年までに市場に参入する可能性のある製薬メーカーにとっては、CGRPベースの治療薬はすべて同様の有効性と安全性プロファイルを持つため、価格設定が差別化の鍵となると思われます。

片頭痛治療薬市場：分析概要

• 治療薬別では、2024年には予防セグメントが62.03%の最大売上シェアで市場をリードしました。急性期セグメントは2024年に第2位の市場収益シェアを占めました。
• 治療クラス別では、CGRPモノクローナル抗体セグメントが2024年に56.68%の最大売上シェアで市場をリードしました。CAGR低分子拮抗薬診断薬セグメントは、予測期間中に最も速いCAGRで成長すると予測されています。
• 投与経路別では、注射剤が2024年に69.48％の最大売上シェアで市場をリードしました。経口剤セグメントは予測期間中に著しいCAGRを示すと予測されています。
• 年齢層に基づくと、成人セグメントは2024年に52.92%の最大収益シェアで市場をリードし、予測期間中に著しいCAGRで成長すると予測されます。老人セグメントは予測期間中CAGRで大きく成長すると予測されます。
• 入手手段別では、処方薬セグメントは2024年に62.38％の最大収益シェアで市場をリードし、予測期間中に著しいCAGRで成長すると予測されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 片頭痛治療薬市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 片頭痛治療薬市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析
• 価格分析
• パイプライン分析：フェーズ別

第4章 片頭痛治療薬市場：治療薬別の推定・動向分析

• 世界の片頭痛治療薬市場：治療薬別のダッシュボード
• 世界の片頭痛治療薬市場：治療薬別の変動分析
• 世界の片頭痛治療薬市場（収益ベース、治療薬別）
• 急性
• 予防

第5章 片頭痛治療薬市場：治療クラス別の推定・動向分析

• 世界の片頭痛治療薬市場：治療クラス別のダッシュボード
• 世界の片頭痛治療薬市場：治療クラス別の変動分析
• 世界の片頭痛治療薬市場（収益ベース、治療クラス別）
• CGRPモノクローナル抗体
• CGRP小分子拮抗薬
• アセチルコリン阻害剤/神経毒
• トリプタン
• ディタンス
• 麦角アルカロイド
• NSAID
• その他

第6章 片頭痛治療薬市場：投与経路別の推定・動向分析

• 世界の片頭痛治療薬市場：投与経路別のダッシュボード
• 世界の片頭痛治療薬市場：投与経路別の変動分析
• 世界の片頭痛治療薬市場（収益ベース、投与経路別）
• 経口薬
• 注射薬
• その他

第7章 片頭痛治療薬市場：年齢層別の推定・動向分析

• 世界の片頭痛治療薬市場：年齢層別のダッシュボード
• 世界の片頭痛治療薬市場：年齢層別の変動分析
• 世界の片頭痛治療薬市場（収益ベース、年齢層別）
• 小児
• 成人
• 高齢者

第8章 片頭痛治療薬市場：入手手段別の推定・動向分析

• 世界の片頭痛治療薬市場：入手手段別のダッシュボード
• 世界の片頭痛治療薬市場：入手手段別の変動分析
• 世界の片頭痛治療薬市場（収益ベース、入手手段別）
• 処方薬
• 市販薬（OTC）

第9章 片頭痛治療薬市場：種類別の推定・動向分析（治療薬別、治療クラス別、投与経路別）

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年まで：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key customers
  • Key company market share analysis, 2023
  • AbbVie Inc.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Eli Lilly and Company
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • Gensco Pharma
  • Impel Pharmaceuticals Inc.
  • Currax Pharmaceuticals LLC.
  • Lundbeck

List of Tables

• Table 1. List of abbreviation
• Table 2. North America Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
• Table 3. North America Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 4. North America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 5. North America Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 6. North America Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 7. North America Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 8. U.S. Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 9. U.S. Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 10. U.S. Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 11. U.S. Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 12. U.S. Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 13. Canada Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 14. Canada Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 15. Canada Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 16. Canada Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 17. Canada Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 18. Europe Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
• Table 19. Europe Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 20. Europe Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 21. Europe Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 22. Europe Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 23. Europe Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 24. Germany Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 25. Germany Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 26. Germany Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 27. Germany Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 28. Germany Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 29. UK Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 30. UK Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 31. UK Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 32. UK Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 33. UK Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 34. France Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 35. France Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 36. France Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 37. France Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 38. France Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 39. Italy Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 40. Italy Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 41. Italy Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 42. Italy Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 43. Italy Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 44. Spain Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 45. Spain Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 46. Spain Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 47. Spain Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 48. Spain Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 49. Denmark Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 50. Denmark Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 51. Denmark Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 52. Denmark Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 53. Denmark Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 54. Sweden Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 55. Sweden Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 56. Sweden Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 57. Sweden Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 58. Sweden Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 59. Norway Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 60. Norway Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 61. Norway Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 62. Norway Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 63. Norway Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 64. Asia Pacific Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
• Table 65. Asia Pacific Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 66. Asia Pacific Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 67. Aisa Pacific Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 68. Asia Pacific Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 69. Aisa Pacific Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 70. China Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 71. China Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 72. China Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 73. China Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 74. China Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 75. Japan Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 76. Japan Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 77. Japan Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 78. Japan Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 79. Japan Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 80. India Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 81. India Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 82. India Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 83. India Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 84. India Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 85. South Korea Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 86. South Korea Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 87. South Korea Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 88. South Korea Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 89. South Korea Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 90. Australia Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 91. Australia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 92. Australia Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 93. Australia Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 94. Australia Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 95. Thailand Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 96. Thailand Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 97. Thailand Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 98. Thailand Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 99. Thailand Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 100. Latin America Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
• Table 101. Latin America Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 102. Latin America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 103. Latin America Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 104. Latin America Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 105. Latin America Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 106. Brazil Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 107. Brazil Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 108. Brazil Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 109. Brazil Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 110. Brazil Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 111. Mexico Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 112. Mexico Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 113. Mexico Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 114. Mexico Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 115. Mexico Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 116. Argentina Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 117. Argentina Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 118. Argentina Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 119. Argentina Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 120. Argentina Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 121. MEA Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
• Table 122. MEA Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 123. MEA Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 124. MEA Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 125. MEA Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 126. MEA Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 127. South Africa Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 128. South Africa Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 129. South Africa Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 130. South Africa Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 131. South Africa Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 132. Saudi Arabia Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 133. Saudi Arabia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 134. Saudi Arabia Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 135. Saudi Arabia Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 136. Saudi Arabia Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 137. UAE Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 138. UAE Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 139. UAE Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 140. UAE Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 141. UAE Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
• Table 142. Kuwait Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
• Table 143. Kuwait Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
• Table 144. Kuwait Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
• Table 145. Kuwait Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
• Table 146. Kuwait Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Migraine Drugs market: market outlook
• Fig. 14 Migraine Drugs competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Migraine Drugs market driver impact
• Fig. 18 Migraine Drugs market restraint impact
• Fig. 19 Migraine Drugs market: Treatment movement analysis
• Fig. 20 Migraine Drugs market: Treatment outlook and key takeaways
• Fig. 21 Acute market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Preventive estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Migraine Drugs market: Therapeutic Class movement analysis
• Fig. 24 Migraine Drugs market: Therapeutic Class outlook and key takeaways
• Fig. 25 CGRP monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 CGRP small molecule antagonists market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Acetylcholine inhibitors/ neurotoxins market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Triptans market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Ditans market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Migraine Drugs market: Route of Administration movement analysis
• Fig. 34 Migraine Drugs market: Route of Administration outlook and key takeaways
• Fig. 35 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Migraine Drugs market: Age Group movement analysis
• Fig. 39 Migraine Drugs market: Age Group outlook and key takeaways
• Fig. 40 Pediatric market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Adult market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Geriatric market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Migraine Drugs market: Availability movement analysis
• Fig. 44 Migraine Drugs market: Availability outlook and key takeaways
• Fig. 45 Prescription Drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Over-the-Counter (OTC) Drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Global Migraine Drugs market: Regional movement analysis
• Fig. 48 Global Migraine Drugs market: Regional outlook and key takeaways
• Fig. 49 Global Migraine Drugs market share and leading players
• Fig. 50 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 US key country dynamics
• Fig. 52 US market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Canada key country dynamics
• Fig. 54 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 UK key country dynamics
• Fig. 57 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Germany key country dynamics
• Fig. 59 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 France key country dynamics
• Fig. 61 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Italy key country dynamics
• Fig. 63 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Spain key country dynamics
• Fig. 65 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Denmark key country dynamics
• Fig. 67 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Sweden key country dynamics
• Fig. 69 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Norway key country dynamics
• Fig. 71 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 China key country dynamics
• Fig. 74 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Japan key country dynamics
• Fig. 76 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 India key country dynamics
• Fig. 78 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Thailand key country dynamics
• Fig. 80 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 South Korea key country dynamics
• Fig. 82 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Australia key country dynamics
• Fig. 84 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Brazil key country dynamics
• Fig. 87 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Mexico key country dynamics
• Fig. 89 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Argentina key country dynamics
• Fig. 91 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 South Africa key country dynamics
• Fig. 94 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Saudi Arabia key country dynamics
• Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 UAE key country dynamics
• Fig. 98 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Kuwait key country dynamics
• Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 101 Market share of key market players - Migraine Drugs market

Migraine Drugs Market Growth & Trends:

The global migraine drugs market size is expected to reach USD 13.34 billion by 2030, registering a CAGR of 10.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis' CGRP mAb Aimovig and Teva Pharma's Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Migraine Drugs Market Report Highlights:

• Based on treatment, the preventive segment led the market with the largest revenue share of 62.03% in 2024. The Acute segment held the second largest market revenue share in 2024.
• Based on the therapeutic class, the CGRP monoclonal antibodies segment led the market with the largest revenue share of 56.68% in 2024. The CGRP small molecule antagonist diagnostics segment is anticipated to grow at the fastest CAGR over the forecast period.
• Based on the route of administration, the injectable segment led the market with the largest revenue share of 69.48% in 2024. The oral segment is projected to witness a significant CAGR over the forecast period.
• Based on age group, the adult segment led the market with the largest revenue share of 52.92% in 2024 and is anticipated to grow at a significant CAGR over the forecast period. The geriatric segment is anticipated to grow at a significant CAGR over the forecast period.
• Based on availability, the prescription drugs segment led the market with the largest revenue share of 62.38% in 2024 and is anticipated to grow at a significant CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Therapeutic Class
  • 1.2.3. Route of Administration
  • 1.2.4. Age Group
  • 1.2.5. Availability
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment and Therapeutic Class outlook
  • 2.2.2. Route of Administration outlook
  • 2.2.3. Age Group and Availability outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Migraine Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of migraines
    • 3.2.1.2. Advancements in drug development
    • 3.2.1.3. Growing awareness and diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of development
    • 3.2.2.2. Regulatory challenges for new drug approvals
• 3.3. Migraine Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis
• 3.5. Pipeline Analysis, by Phase

Chapter 4. Migraine Drugs Market: Treatment Estimates & Trend Analysis

• 4.1. Global Migraine Drugs Market: Treatment Dashboard
• 4.2. Global Migraine Drugs Market: Treatment Movement Analysis
• 4.3. Global Migraine Drugs Market by Treatment, Revenue
• 4.4. Acute
  • 4.4.1. Acute market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Preventive
  • 4.5.1. Preventive market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Migraine Drugs Market: Therapeutic Class Estimates & Trend Analysis

• 5.1. Global Migraine Drugs Market: Therapeutic Class Dashboard
• 5.2. Global Migraine Drugs Market: Therapeutic Class Movement Analysis
• 5.3. Global Migraine Drugs Market by Therapeutic Class, Revenue
• 5.4. CGRP monoclonal antibodies
  • 5.4.1. CGRP monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. CGRP small molecule antagonists
  • 5.5.1. CGRP small molecule antagonists market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Acetylcholine inhibitors/ neurotoxins
  • 5.6.1. Acetylcholine inhibitors/ neurotoxins market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Triptans
  • 5.7.1. Triptans market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Ditans
  • 5.8.1. Ditans market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.9. Ergot alkaloids
  • 5.9.1. Ergot alkaloids market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.10. NSAIDs
  • 5.10.1. NSAIDs market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Migraine Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Migraine Drugs Market: Route of Administration Dashboard
• 6.2. Global Migraine Drugs Market: Route of Administration Movement Analysis
• 6.3. Global Migraine Drugs Market by Route of Administration, Revenue
• 6.4. Oral
  • 6.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Injectable
  • 6.5.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Migraine Drugs Market: Age Group Estimates & Trend Analysis

• 7.1. Global Migraine Drugs Market: Age Group Dashboard
• 7.2. Global Migraine Drugs Market: Age Group Movement Analysis
• 7.3. Global Migraine Drugs Market by Age Group, Revenue
• 7.4. Pediatric
  • 7.4.1. Pediatric market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Adult
  • 7.5.1. Adult market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Geriatric
  • 7.6.1. Geriatric market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Migraine Drugs Market: Availability Estimates & Trend Analysis

• 8.1. Global Migraine Drugs Market: Availability Dashboard
• 8.2. Global Migraine Drugs Market: Availability Movement Analysis
• 8.3. Global Migraine Drugs Market by Availability, Revenue
• 8.4. Prescription Drugs
  • 8.4.1. Prescription Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. Over-the-Counter (OTC) Drugs
  • 8.5.1. Over-the-Counter (OTC) Drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Migraine Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.7. Middle East & Africa
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2023
  • 10.3.4. AbbVie Inc.
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Amgen Inc.
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Teva Pharmaceutical Industries Ltd.
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. GSK plc
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Eli Lilly and Company
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Pfizer Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Bausch Health Companies Inc.
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Gensco Pharma
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Impel Pharmaceuticals Inc.
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Currax Pharmaceuticals LLC.
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Lundbeck
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives